Compounded GLP-1 Drug Recalled Nationwide Over Sterility Concerns

Apothecary Pharma LLC has initiated a nationwide voluntary recall of 22 vials of compounded tirzepatide, a GLP-1 drug, due to a 'lack of assurance of sterility.' The recall also includes one vial of NAD+ injection. The U.S. Food and Drug Administration (FDA) classified this as a Class II recall, meaning exposure may cause temporary or reversible adverse health consequences, with a low probability of serious harm. This action follows a December 2025 FDA warning letter to the company regarding deficiencies in sterile drug production practices.